Sometimes you can do everything right and still get punished. That's the story playing out at Boston Scientific Corporation (BSX) on Wednesday, where the medical device maker delivered a solid quarter but watched its stock crater to a fresh 52-week low anyway.

The company reported fourth-quarter revenues of $5.29 billion, essentially matching the consensus estimate of $5.28 billion while comfortably beating management's own guidance range of $5.22 billion to $5.31 billion. Adjusted earnings came in at 80 cents per share, topping both the 78-cent consensus and the company's guidance of 77 to 79 cents.

Sales growth looked healthy across the board. Revenue jumped 15.9% on a reported basis, ahead of the company's 14.5%-16.5% guidance range. Operationally, sales grew 14.3%, and organically they climbed 12.7%, surpassing the 11%-13% guidance range.

Cardiovascular Segment Powers Growth

The cardiovascular division did the heavy lifting, generating $3.48 billion in sales with an 18.2% reported increase (16.5% operationally, 16.1% organically). Breaking it down further: interventional Cardiology & Vascular Therapies grew 7% organically to $1.20 billion, Watchman sales surged 29% to $535 million, Electrophysiology jumped an impressive 35% to $890 million, while Cardiac Rhythm Management edged up just 1% to $587 million.

The MedSurg segment also delivered respectable numbers, with revenues hitting $1.81 billion—up 11.7% on a reported basis, 10.2% operationally, and 6.5% organically. Endoscopy led this group with $760 million in sales, up 10.1%. Neuromodulation rose 11.1% to $332 million, and Urology climbed 13.8% to $717 million.

Margins held steady too, with adjusted gross margin coming in at 70.7% and operating margin at 27.3%, both virtually unchanged from the prior year.

The Problem: Underwhelming 2026 Guidance

So what spooked investors? The 2026 outlook. Boston Scientific forecasts net sales growth of approximately 10.5%-11.5% on a reported basis and 10%-11% organically, translating to revenue between $22.18 billion and $22.38 billion. The midpoint sits right around the $22.37 billion consensus, but apparently that's not exciting enough after the company's recent performance.

Adjusted earnings are expected to land between $3.43 and $3.49 per share, compared to the consensus of $3.47—again, right in line but offering little upside surprise.

For the first quarter of 2026, the company expects sales growth of 10.5%-12% on a reported basis and 8.5%-10% organically, which should yield $5.13 billion to $5.22 billion in revenue versus the $5.20 billion consensus. Adjusted earnings are projected at 78 to 80 cents per share, compared to the 79-cent consensus. A company executive noted that foreign exchange should provide a roughly 200 basis point tailwind to first-quarter results.

AXIOS Stent Safety Concerns Add Pressure

Making matters worse, there's a safety issue hanging over the company. In January, the U.S. Food and Drug Administration announced that Boston Scientific had advised customers to remove certain AXIOS stents and electrocautery-enhanced delivery systems from use after reports of deployment and expansion problems that could seriously harm patients.

According to the FDA, the company sent a letter on December 19, 2025, instructing customers to immediately stop using and distributing the affected devices. Some AXIOS systems have shown increased difficulty in stent deployment during procedures, though already-implanted stents aren't affected.

The numbers are concerning: as of December 23, Boston Scientific had reported 167 serious injuries and three deaths linked to the issue. These devices are used for endoscopic drainage of pancreatic pseudocysts and walled-off necrosis, as well as gallbladder drainage in high-risk patients with acute cholecystitis. The company has instructed healthcare facilities to remove the products from inventory and return them, while the FDA continues its review.

Boston Scientific shares dropped 15.76% to $77.18 on Wednesday, marking a new 52-week low. Sometimes beating the numbers just isn't enough when guidance disappoints and regulatory concerns loom large.